Methotrexate and Childhood Leukemia

References

• Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin). N Engl J Med 1948; 238: 787–793
   PubMed Web of Science ®Google Scholar
• Stephen P, Schilsky A, Schilsky RL. High-dose methotrexate: A critical reappraisal. J Clin Oncol 1987; 5: 2017–2031
   PubMed Web of Science ®Google Scholar
• Folate Antagonists as Therapeutic Agents., FM Sirotnak, JJ Burchall, WE Ensminger, JA Montgomery. Academic Press, New York 1984
   Google Scholar
• Mitchell JJ, Snell EE, Williams RJ. The concentration of ‘folic acid.’. J Am Chem Soc 1941; 62: 2284
   Google Scholar
• Angier RB, Boothe JH, Hutchings BL. Synthesis of a compound identical with theL. caseifactor isolated from liver. Science 1945; 102: 227–228
   PubMed Web of Science ®Google Scholar
• Angier RB, Boothe JH, Hutchings BL. The structure and synthesis of the liverL. caselfactor. Science 1946; 102: 667–669
   Google Scholar
• Elion GB, Burgi E, Hitchings GH. Studies on condensed pyrimidine systems. IX. The synthesis of some 6-substituted purines. J Am Chem Soc 1952; 74: 411–414
   Web of Science ®Google Scholar
• Law LW. Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. Cancer Res 1952; 12: 871–878
   PubMed Web of Science ®Google Scholar
• Goldin A, Mantel N, Greenhouse SW, et al. Effect of delayed administration of citrovorum factor on the antileukemic effectiveness of aminopterin in mice. Cancer Res 1953; 43–48
   Web of Science ®Google Scholar
• Goldin A, Venditti JM, Humphreys SR, et al. Modification of treatment schedules in the management of advanced mouse leukemia with amethopterin. J Natl Cancer Inst 1952; 17: 203–212
   Google Scholar
• Frei E, Freireich EJ, Gehan E. Acute leukemia group B, studies of sequential and combination antimetabolite therapy in acute leukemia:6-mercaptopurine and methotrexate. Blood 1961; 18: 431
   Web of Science ®Google Scholar
• Frei E, Freireich EJ, Gehan E. Acute leukemia Group B, new treatment schedule with improved survival in childhood leukemia. JAMA 1965; 194: 187–193
   PubMedGoogle Scholar
• Frei E, Freireich EJ, Gehan E. Acute Leukemia Group B: Acute lymphocytic leukemia in children; maintenance therapy with methotrexate administered intermittently. JAMA 1969; 207: 923
   PubMed Web of Science ®Google Scholar
• Frei E, III, Karon J, Levin RH, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965; 26: 642
   PubMed Web of Science ®Google Scholar
• Simone J, Aur R, Hustu O, et al. ‘Total Therapy’ studies of acute lymphocytic leukemia in children. Cancer 1972; 30: 1488–1494
   PubMed Web of Science ®Google Scholar
• Freireich E. Acute leukemia. A prototype of disseminated cancer. Cancer 1984; 53: 2026–2033
   PubMed Web of Science ®Google Scholar
• Moe PJ, Seip M, Finne PH. Intermediate dose methotrexate (IDM) in childhood acute lymphocytic leukemia in Norway. Preliminary results of a national treatment program. Acta Paediatr Scand 1981; 70: 73–79
   PubMed Web of Science ®Google Scholar
• Freeman AI, Weinberg V, Brecher ML, et al. Comparison of intermediate-dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 1983; 308: 477–484
   PubMed Web of Science ®Google Scholar
• Green DM, Brecher ML, Blumenson LE, et al. The use of intermediate dose methotrexate in increased risk childhood acute lymphoblastic leukemia. A comparison of three versus six courses. Cancer 1982; 50: 2722–2727
   PubMed Web of Science ®Google Scholar
• Abromowitch M, Ochs J, Pui GH, et al. Efficacy of high dose methotrexate in childhood acute lymhocytic leukemia: Analysis by contemporary risk classifications. Blood 1988; 71: 866–869
   PubMed Web of Science ®Google Scholar
• Sansone G. Pathomorphosis of acute infantile leukaemia treated with modern therapeutic agents; ‘meningoleukaemia’ and Frolich's obesity. Annales Paediatrici 1954; 183: 33–42
   PubMedGoogle Scholar
• Whiteside JA, Philips FS, Dargeon HW, et al. Intrathecal amethopterin in neurological manifestations of leukaemia. Arch Intern Med. 1958; 101: 279–285
   Web of Science ®Google Scholar
• Pinkel D. Treatment of acute lymphocytic leukemia. Cancer 1979; 43: 1128–1137
   PubMed Web of Science ®Google Scholar
• Thyss A, Milano G, Etienne MC, et al. Evidence for CSF accumulation of 5-methyletrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer 1989; 49: 627–630
   Google Scholar
• Kamen BA, Vietti T. Letter to the editor. Br J Cancer 1989; 60: 799
   PubMedGoogle Scholar
• Sullivan M, Chen T, Dyment P, et al. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis children with acute lymphatic leukemia: A Pediatric Oncology Group Blood. 1982; 60: 948–958
   Google Scholar
• Parker D, Bate CM, Craft AW, et al. Liver damage in children with acute leukemia and non-Hodgkin's lymphoma on oral maintenance chemotherapy. Cancer Chemother Pharmacol, 4: 121–127
   PubMed Web of Science ®Google Scholar
• Proceedings of the High-Dose Methotrexate Therapy Meeting:December 19, 1974. Cancer Chemotherapy Reports Part 3 July, 1975; Vol. 6(No. 1)
   Google Scholar
• Sostman HD, Matthay RA, Putman EC, et al. Methotrexate-induced pneumonitis. Medicine 1976; 55(5)371–388
   PubMed Web of Science ®Google Scholar
• Abelson HT. Methotrexate and central nervous system toxicity. Cancer Treat Rep 1978; 62: 1999
   PubMedGoogle Scholar
• Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981; 65: 89
   PubMedGoogle Scholar
• Liu HM, Maurer HS, Vongsvivut S, et al. Methotrexate encephalopathy. A neuropathologic study. Human Pathol 1978; 9: 635
   PubMed Web of Science ®Google Scholar
• Kamen BA, Moulder JE, Kun LE, et al. Effects of single dose and fractionated cranial irradiation on rat brain accumulation of methotrexate. Cancer Res, 44: 5092–5094
   PubMed Web of Science ®Google Scholar
• Winick NJ, Kamen BA, Balis FM, et al. Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. Cancer Drug Del 1987; 4(1)25–31
   PubMedGoogle Scholar
• Kamen BA. Folate, MTx and the brain. J Neurotoxicol 1986; 7: 209–216
   PubMed Web of Science ®Google Scholar
• Schonagel JH, McVie JG. The clinical pharmacology of methotrexate. Cancer Treat Rev 1983; 10: 53–75
   Web of Science ®Google Scholar
• Sirotnak FM. Obligate genetic expression in tumor cells of a fetal membrane property mediating ‘folate’ transport: biological significance and implications for improved therapy of human cancer. Cancer Res 1985; 45: 3992–4000
   PubMed Web of Science ®Google Scholar
• Anthony A, Kane M, Portillo R, et al. Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J Biol Chem 1985; 26: 14911–14917
   Google Scholar
• McHugh M, Cheng Y. Demonstration of a high affinity folate binder in human cell membrane and its characterization in cultured human KB cells. J Biol Chem 1979; 24(22)11312–11318
   Google Scholar
• Kamen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci (USA) 1986; 83: 5983–5987
   PubMed Web of Science ®Google Scholar
• Sirotnak FM, Goutas LJ, Jacobsen DM, et al. Carrier-mediated transport of folate compounds in L1210 cells. Biochem Pharmacol 1987; 36(10)1659–1667
   PubMedGoogle Scholar
• Price EM, Freisheim JH. Photoaffinity analogues of methotrexate as folate antagonist binding probes. 2. Transport studies, photoaffinity labeling, and identification of the membrane carrier protein for methotrexate from murine L1210 cells. Biochemistry 1987; 26: 4757–4763
   PubMed Web of Science ®Google Scholar
• Taylor S, McGuire W, Hauck W, et al. A randomized comparison of high-dose infusion methotrexate versus standard dose weekly therapy in head and neck squamous cancer. J Clin Oncol 1984; 2: 1006–1011
   PubMed Web of Science ®Google Scholar
• Vogler W, Jacobs J, Miffits S, et al. Methotrexate therapy with or without citrovorum factor in carcinoma of the head and neck, breast, and colon. Cancer Clin Trials 1979; 2: 227–236
   Google Scholar
• Kirkwood J, Canellos G, Ervin T, et al. Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck; a safe new effective regimen. Cancer 1981; 47: 2414–2421
   PubMed Web of Science ®Google Scholar
• Kamen B. Folic acid antagonists. Metabolism and Action of Anti-Cancer Drugs, G. Powis, RA. Prough. Taylor & Francis, Philadelphia 1987; 141–162
   Google Scholar
• Baugh CM, Krumdieck CL, Nair MG. Polygammaglutamyl metabolites of methotrexate. Biochem Biophys Res Commun 1937; 52: 27
   Google Scholar
• Jacobs SA, Derr CJ, Johns DG. Accumulation of methotrexate diglutamate in human liver during methotrexate therapy. Biochem Pharmacol 1977; 26: 2310–2313
   PubMed Web of Science ®Google Scholar
• Kremer J, Galivan J, Streckfuss A, et al. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Arthritis Rheum 1986; 29: 823–835
   Google Scholar
• Allegra CJ, Drake JC, Jolivet J, et al. Inhibition of phosphoribosyl aminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci (USA), 82: 4881–4885
   PubMed Web of Science ®Google Scholar
• Djerassi I, Farber S, Abir E, et al. Continuous infusion of methotrexate in children with acute leukemia. Cancer 1967; 20: 233–242
   PubMed Web of Science ®Google Scholar
• Camitta BM, Leventhal B, Lauer S, et al. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 1989; 7: 1539–1544
   PubMed Web of Science ®Google Scholar
• Bokkerink JPM, De Abreu RA, Bakker MAH, et al. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages. Biochem Pharm 1988; 37: 2329–2338
   PubMed Web of Science ®Google Scholar
• Bokkerink JPM, Marinka AH, Bakker MAH, et al. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharm 1988; 37: 2321–2327
   PubMed Web of Science ®Google Scholar